Advertisement

Research Article Free access | 10.1172/JCI119098

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C Serradeil-Le Gal, C Lacour, G Valette, G Garcia, L Foulon, G Galindo, L Bankir, B Pouzet, G Guillon, C Barberis, D Chicot, S Jard, P Vilain, C Garcia, E Marty, D Raufaste, G Brossard, D Nisato, J P Maffrand, and G Le Fur

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Serradeil-Le Gal, C. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Lacour, C. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Valette, G. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Garcia, G. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Foulon, L. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Galindo, G. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Bankir, L. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Pouzet, B. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Guillon, G. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Barberis, C. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Chicot, D. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Jard, S. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Vilain, P. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Garcia, C. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Marty, E. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Raufaste, D. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Brossard, G. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Nisato, D. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Maffrand, J. in: JCI | PubMed | Google Scholar

Sanofi Recherche, Exploratory Research Department, Toulouse, France.

Find articles by Le Fur, G. in: JCI | PubMed | Google Scholar

Published December 15, 1996 - More info

Published in Volume 98, Issue 12 on December 15, 1996
J Clin Invest. 1996;98(12):2729–2738. https://doi.org/10.1172/JCI119098.
© 1996 The American Society for Clinical Investigation
Published December 15, 1996 - Version history
View PDF
Abstract

SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human kidney (0.6 < or = Ki [nM] < or = 4.1). In this latter preparation, SR 121463A potently antagonized arginine vasopressin (AVP)-stimulated adenylyl cyclase activity (Ki = 0.26+/-0.04 nM) without any intrinsic agonistic effect. In autoradiographic experiments performed in rat kidney sections, SR 121463A displaced [3H]AVP labeling especially in the medullo-papillary region and confirmed that it is a suitable tool for mapping V2 receptors. In comparison, the nonpeptide V2 antagonist, OPC-31260, showed much lower affinity for animal and human renal V2 receptors and lower efficacy to inhibit vasopressin-stimulated adenylyl cyclase (Ki in the 10 nanomolar range). Moreover, OPC-31260 exhibited a poor V2 selectivity profile and can be considered as a V2/V1a ligand. In normally hydrated conscious rats, SR 121463A induced powerful aquaresis after intravenous (0.003-0.3 mg/kg) or oral (0.03-10 mg/kg) administration. The effect was dose-dependent and lasted about 6 hours at the dose of 3 mg/kg p.o. OPC-31260 had a similar aquaretic profile but with markedly lower oral efficacy. The action of SR 121463A was purely aquaretic with no changes in urine Na+ and K+ excretions unlike that of known diuretic agents such as furosemide or hydrochlorothiazide. In addition, no antidiuretic properties have been detected with SR 121463A in vasopressin-deficient Brattleboro rats. Thus, SR 121463A is the most potent and selective, orally active V2 antagonist yet described and could be a powerful tool for exploring V2 receptors and the therapeutical usefulness of V2 blocker aquaretic agents in water-retaining diseases.

Version history
  • Version 1 (December 15, 1996): No description
Advertisement
Advertisement